Placebo News and Research

RSS

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

Prolonged exposure therapy does not increase drinking in PTSD and alcohol dependent patients

Contrary to past concerns, using prolonged exposure therapy to treat patients with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence does not increase drinking or cravings, Penn Medicine psychiatrists report in the August 7 issue of JAMA, a theme issue on violence/human rights.

7 Aug 2013

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67 percent in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA).

6 Aug 2013

Added benefit of thyroid cancer drug vandetanib not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products.

3 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

New technique accelerate tissue repair, reduce costs for chronic wound management

In a small clinical study, researchers administered a new method for treating chronic wounds using a novel ultrasound applicator that can be worn like a band-aid. The applicator delivers low-frequency, low-intensity ultrasound directly to wounds, and was found to significantly accelerate healing in five patients with venous ulcers.

2 Aug 2013

Pharmanest announces positive results from SHACT Phase II study

Karolinska Development: Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT. The data show that SHACT is effective in reducing pain in connection with intrauterine device insertion. Karolinska Development owns 63% of Pharmanest.

1 Aug 2013

Experts say action needed urgently to ensure India's new policy does not backfire

In an editorial published online today in BMJ, Johns Hopkins bioethicist Jeremy Sugarman and other experts warn that action is urgently needed to deal with possible unintended consequences of India's new policy protecting research participants.

1 Aug 2013

Oxytocin hormone affects men and women differently, research finds

"The Love Hormone", Oxytocin affects men and women differently in social contexts- in men it improves the ability to identify competitive relationships whereas in women it facilitates the ability to identify kinship. "These findings are in agreement with previous studies on the social differences between the sexes: women tend to be more communal and familial in their behavior, whereas men are more inclined to be competitive and striving to improve their social status", said Prof. Simone Shamay-Tsoory from the Dept. of Psychology at the University of Haifa who led the research.

1 Aug 2013

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found.

31 Jul 2013

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Sosei Group Corporation confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Prana Biotechnology today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.

23 Jul 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Placebo News and Research

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Prolonged exposure therapy does not increase drinking in PTSD and alcohol dependent patients

Isis Pharmaceuticals announces results of ISIS-CRPRx Phase 2 study in RA patients

Added benefit of thyroid cancer drug vandetanib not proven

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

New technique accelerate tissue repair, reduce costs for chronic wound management

Pharmanest announces positive results from SHACT Phase II study

Experts say action needed urgently to ensure India's new policy does not backfire

Oxytocin hormone affects men and women differently, research finds

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News